CA2254819A1 - Inhibition de la replication du vih-1 au moyen de l'expression d'arn antisens - Google Patents

Inhibition de la replication du vih-1 au moyen de l'expression d'arn antisens Download PDF

Info

Publication number
CA2254819A1
CA2254819A1 CA002254819A CA2254819A CA2254819A1 CA 2254819 A1 CA2254819 A1 CA 2254819A1 CA 002254819 A CA002254819 A CA 002254819A CA 2254819 A CA2254819 A CA 2254819A CA 2254819 A1 CA2254819 A1 CA 2254819A1
Authority
CA
Canada
Prior art keywords
hiv
antisense
cells
sequence
pol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002254819A
Other languages
English (en)
Inventor
Ernst Boehnlein
Sonia Escaich
Heini Ilves
Gabor Veres
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Systemix Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2254819A1 publication Critical patent/CA2254819A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des nouvelles séquences antisens ayant pour cible des portions à épissage simple ou non épissées d'un produit de transcription d'ARNm provenant du provirus du VIH de type 1 (VIH-1), éventuellement exprimées en même temps qu'une protéine du VIH-1 mutante, transdominante et inhibitrice. Ces séquences sont utiles dans le traitement de l'infection à VIH-1.
CA002254819A 1996-06-06 1997-06-06 Inhibition de la replication du vih-1 au moyen de l'expression d'arn antisens Abandoned CA2254819A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1923296P 1996-06-06 1996-06-06
US60/019,232 1996-06-06

Publications (1)

Publication Number Publication Date
CA2254819A1 true CA2254819A1 (fr) 1997-12-11

Family

ID=21792127

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002254819A Abandoned CA2254819A1 (fr) 1996-06-06 1997-06-06 Inhibition de la replication du vih-1 au moyen de l'expression d'arn antisens

Country Status (7)

Country Link
EP (1) EP0914423A2 (fr)
JP (1) JP2001502884A (fr)
AU (1) AU717233B2 (fr)
CA (1) CA2254819A1 (fr)
IL (1) IL127038A0 (fr)
NZ (1) NZ333190A (fr)
WO (1) WO1997046673A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
AU7104200A (en) * 2000-09-01 2002-03-22 Gen Probe Inc Amplification of hiv-1 sequences for detection of sequences associated with drug-resistance mutations
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
JP5461459B2 (ja) * 2011-03-01 2014-04-02 ジェン−プローブ・インコーポレーテッド 薬剤耐性突然変異と関連する配列検出のためのｈｉｖ−１配列の増幅
JP5461460B2 (ja) * 2011-03-01 2014-04-02 ジェン−プローブ・インコーポレーテッド 薬剤耐性突然変異と関連する配列検出のためのｈｉｖ−１配列の増幅
JP2012105648A (ja) * 2011-12-12 2012-06-07 Gen Probe Inc 薬剤耐性突然変異と関連する配列検出のためのｈｉｖ−１配列の増幅
US9932364B2 (en) 2013-08-26 2018-04-03 The Royal Institution For The Advancement Of Learning/Mcgill University Antisense-based small RNA agents targeting the Gag open reading frame of HIV-1 RNA

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014427A2 (fr) * 1989-05-25 1990-11-29 Sandoz Ltd Represseur polyvalent de fonctions geniques
EP0598935A1 (fr) * 1992-11-24 1994-06-01 Bayer Ag Vecteurs d'expression et leur utilisation pour la production de cellules humaines résistantes à HIV pour utilisation thérapeutique
IL108719A0 (en) * 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them

Also Published As

Publication number Publication date
NZ333190A (en) 2001-03-30
EP0914423A2 (fr) 1999-05-12
JP2001502884A (ja) 2001-03-06
WO1997046673A3 (fr) 1998-01-15
WO1997046673A2 (fr) 1997-12-11
AU717233B2 (en) 2000-03-23
AU3255897A (en) 1998-01-05
IL127038A0 (en) 1999-09-22

Similar Documents

Publication Publication Date Title
Srinivasakumar et al. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines
Nguyen et al. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression
US5994108A (en) Mutant TAR virus and transdominant tat mutants as pharmacological agents
WO1996007741A1 (fr) Proteine pour ciblage dans des virions de vih sur la base de molecules de fusion vih-1/vpr
US5554528A (en) Compositions and methods for inhibition of HIV production
JP2004524813A (ja) 改良された条件付けで複製するベクター類、それらの生成及び使用方法
US6776986B1 (en) Inhibition of HIV-1 replication by antisense RNA expression
Inouye et al. Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector
AU717233B2 (en) Inhibition of HIV-1 replication by antisense RNA expression
Paik et al. Defective HIV-1 provirus encoding a multitarget-ribozyme inhibits accumulation of spliced and unspliced HIV-1 mRNAs, reduces infectivity of viral progeny, and protects the cells from pathogenesis
JP2002542791A (ja) 真核生物中で活性を有するレトロウイルスタンパク質を発現させるための合成遺伝子
Mautino et al. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense
WO1993005147A1 (fr) Particules defectives interferentes du vih avec un cd-env chimerique
PENG et al. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector
US5837503A (en) Vector containing viral gene transcribed by RNA polymerase III and methods for use
AU2003242496B2 (en) Conjugate
WO1995031477A1 (fr) Vecteurs a sequences tar multiples du vih-1 inhibant l'expression genique du vih-1
WO1995027783A1 (fr) Inhibition de la multiplication du vih-1 dans des cellules de mammiferes
EP0682708B1 (fr) Composition de variants transdominants de proteines virales pour un effet antiviral
US20060067948A1 (en) Viral vectors
WO1996028189A1 (fr) Gene de fusion transdominant double et proteine
JP3805371B2 (ja) 細胞にｈｉｖ重感染に対する抵抗性を与える組成物および方法
Statham Comparison of decoy and antisense transcripts to inhibit HIV-1 replication by gene transfer
Heusch Preclinical development of ribozyme gene therapy for primate lentiviruses
Nazari RNA and DNA inactivation strategies to prevent or inhibit HIV-1 replication via gene therapy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued